(Q36634252)

15 August 2017

1 reference

title

Emerging treatments for pulmonary arterial hypertension. (English)

1 reference

15 August 2017

Erika B Rosenzweig

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

11

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

609-619

1 reference

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Dilated Cardiomyopathy and the Desmin Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

The new clinical trials on pharmacological treatment in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Hemodynamic effects of iloprost, a prostacyclin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small-bowel obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

A role for platelet-derived growth factor beta-receptor in a newborn rat model of endothelin-mediated pulmonary vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

PDGF signaling in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Myosin phosphatase: structure, regulation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Pulmonary arterial hypertension: new insights and new hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

Imatinib Mesylate in the Treatment of Refractory Idiopathic Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.4.609

10.1517/14728214.11.4.609

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference